The Journal of PHARMACOLOGY And Experimental Therapeutics

Correction to: "Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport."

The corresponding author of the above article [Kulkarni P, Korzekwa, K, Nagar, S (2016) *J Pharmacol Exp Ther* **359**:26-36. DOI: https://doi.org/10.1124/jpet.116.235689], Swati Nagar has recently identified an error.

In the modeling exercise, the CLo was inadvertently fixed in the Atv+ABT+RIF dataset, resulting in a value of fum = 0.54 instead of the experimentally obtained fum = 0.84. While literature values of fum of 0.56 have been reported (Watanabe et al, Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans, Drug Metabolism and Disposition, 2010, 38:215-222), the intent of this work was to use the experimentally obtained value of 0.84. This error resulted in an inaccurate estimation of CLae. The CLae estimate is increased by a factor of 20 (88, 82, and 70 ml/min instead of 4.4, 4.1 and 3.5 ml/min respectively, Table 1). Use of the correct fum and CLae estimates increases the predicted unbound intracellular concentration at 50 min for the Atv+ABT+RIF dataset (passive diffusion only) from 0.58 μM (Table 3) to 0.9 μM.

The impact of active uptake on predicted unbound intracellular concentration is unchanged (0.9 and 8.14 μM Atv+ABT+RIF and Atv+ABT respectively) compared to the previously Atv+ABT+published results (0.58 and 6.5 μM RIF and Atv+ABT respectively, Table 3).

These corrections do not change the overall results and conclusions in the article.

The authors apologize for the error.

Downloaded from jpet.aspetjournals.org at ASPET Journals on January 26, 2023